Study on the importance of cellular immune response in malignant tumors, autoimmune diseases, immunodeficiency syndromes, after organ transplantation and during pregnancy

Study on the importance of cellular immune response in malignant tumors, autoimmune diseases, immunodeficiency syndromes, after organ transplantation and during pregnancy - IMMUCAN

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00008016

Enrollment

1000

Registered

2017-09-21

Start date

2011-08-01

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer, Autoimmune Diseases, Immune Deficiency Syndromes, Pregnancy

Interventions

Group 1: Patients with immune regulation (cancer diseases, autoimmune diseases, immune deficiency syndromes, organ transplants) and pregnant women: Blood is taken after written consent in addition to

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients: malignant tumor, autoimmune disease, immunodeficiency syndrome, state after organ transplantation, pregnancy. Control group: healthy volunteers All of them: written consent

Exclusion criteria

Exclusion criteria: No written informed consent. Contraindication for additional blood sampling.

Design outcomes

Primary

Measure	Time frame
Cross-sectional and correlation analysis using flow cytometry and immunohistology of circulating and tissue-resident immune cells in patients and healthy control subjects.	—

Countries

Germany

Contacts

Public ContactMichael von Bergwelt-Baildon

Universitätsklinikum Köln,Klinik I für Innere Medizin, Interventionelle Immunologie Köln

michael.bergwelt@uk-koeln.de+49 221 478-86720

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026